Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST
Posts Posts by: "Amplion"

There are now three approved drugs that target PD-1 either directly or indirectly, and more are under development.While these drugs all seek to inhibit PD-1’s immune suppressive activity, they are quite different in the ways that companion diagnostic tests play a role in their use. Nivolumab (OPDIVO®) – This antibody from Bristol…(Read More)

This article was originally published on WSJ.com by Charley Grant on May 30, 2016. Novel cancer treatments are the next big hope for the drug sector. But investors shouldn’t forget that reward goes hand in hand with risk. Download the full report: Clincial Development Success Rates: 2006-2015…(Read More)

Biomarkers triple clinical trial success rate, says report By Melissa Fassbender, 26-May-2016 A recent study of clinical drug development success rates found that biomarker-enabled drug programs are three times more likely to reach approval. http://www.outsourcing-pharma.com/Preclinical-Research/Biomarkers-triple-clinical-trial-success-rate-says-report Download the full…(Read More)

This article was originally published on Fortune.com, by Sy Mukherjee May 26, 2016. But there’s good reason to hope that may change very soon. This post was corrected/updated on Monday, May 30. A massive new study of drug candidates sheds light on which experimental therapies are most likely to eventually reach the…(Read More)

New Report from Amplion, BIO, and BioMedTracker examined ~10,000 clinical trials to make groundbreaking conclusion regarding biomarkers. Bend, Ore., May 25, 2016., May 25, 2016 – Amplion (inventors of BiomarkerBaseTM), Biomedtracker, and BIO announces the publication of the largest study of clinical drug development success rates ever. The report examines ~10,000 clinical programs by…(Read More)

Some time back, FDA alluded to a new category of biomarker termed “complementary diagnostic.”  This was the Agency’s first use of a categorization beyond “companion diagnostic.” Since then there have been several public announcements of new “complementary diagnostic” tests, or expanded indications for existing tests, but no definition forthcoming from FDA. By contrast, the…(Read More)

New Report from Amplion, BIO, and BioMedTracker examined ~10,000 clinical trials to make groundbreaking conclusion regarding biomarkers. 09:25 ET from Amplion BEND, Ore., May 25, 2016 /PRNewswire/ — Amplion (inventors of BiomarkerBase™), Biomedtracker, and BIO announces the publication of the largest study of clinical drug development success rates ever. The report examines ~10,000…(Read More)

This article was originally published on Boston Business Journal on May 25, 2016 by Don Seiffert A report released today by the biotech industry’s national trade group finds less than one of every 10 drugs that enter clinical trials is ultimately approved by the Food and Drug Administration. The report is sponsored by the…(Read More)

This article was originally published on PharmTech.com by Randi Hernandez on May 25, 2016. In collaboration with Amplion, a biomarker business intelligence company, and BioMedtracker, a service that tracks a drug’s likelihood of approval (LOA) by FDA, the Biotechnology Innovation Organization (BIO) released a report on May 25, 2016 that examined clinical trial…(Read More)

On January 29th, we posted a CotW outlining the top 10 pharma companies by number of unique biomarkers those companies are using in trials.  We thought it was about time to update that chart and expand it to the top 25 pharma companies. Interesting facts to note: Trials are added and changed so frequently that…(Read More)